Genprex Reports Positive Clinical Biomarker Data for Reqorsa Gene Therapy at ASCO
Summary
Genprex reported positive clinical data from its Reqorsa gene therapy trials, identifying biomarkers that predict treatment efficacy in lung cancer patients.
Key Events
-
Positive Clinical Biomarker Data
Research collaborators published an abstract at the 2026 ASCO Annual Meeting detailing positive clinical data for Reqorsa Gene Therapy in lung cancer.
-
Predictive Biomarkers Identified
High Trop-2 levels and low PTEN levels correlated with prolonged Progression Free Survival (PFS) in Non-Small Cell Lung Cancer (NSCLC) patients treated with Reqorsa.
-
Supports Precision Medicine
These identified biomarkers may predict patient response, enable targeted patient selection, and advance precision medicine for Reqorsa.
Analysis
Genprex announced positive clinical data from its Acclaim trials, identifying predictive biomarkers (high Trop-2 and low PTEN levels) that correlate with prolonged Progression Free Survival in Non-Small Cell Lung Cancer patients treated with Reqorsa. This clinical validation of biomarkers is crucial for targeted patient selection and advancing precision medicine, offering a significant positive development for a company facing a going concern warning and Nasdaq delisting threats.
At the time of this filing, GNPX was trading at $0.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $0.74 to $55.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.